ARTA
ITCI

A.R.T. Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

A.R.T. Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,921
Closed -$649K – 1050
2019
Q4 		$649K Sell
18,921
-125,000
-87% -$1.5M 0.03% 732
2019
Q3 		$1.07M Buy
143,921
+110,700
+333% +$1.06M 0.05% 519
2019
Q2 		$431K Buy
33,221
+6,403
+24% +$82.1K 0.02% 806
2019
Q1 		$327K Sell
26,818
-16,178
-38% -$207K 0.02% 904
2018
Q4 		$490K Buy
42,996
+3,900
+10% +$63K 0.03% 743
2018
Q3 		$848K Sell
39,096
-20,700
-35% -$433K 0.04% 653
2018
Q2 		$1.06M Buy
+59,796
New +$1.21M 0.04% 613
2018
Q1 		– Sell
-81,010
Closed -$1.17M – 1803
2017
Q4 		$1.17M Sell
81,010
-60,147
-43% -$929K 0.05% 559
2017
Q3 		$2.23M Buy
141,157
+89,464
+173% +$1.31M 0.11% 243
2017
Q2 		$642K Sell
51,693
-49,507
-49% -$574K 0.03% 688
2017
Q1 		$1.64M Buy
101,200
+1,900
+2% +$27.5K 0.08% 382
2016
Q4 		$1.5M Buy
+99,300
New +$1.4M 0.09% 353

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

A.R.T. Advisors's ITCI Position: Q1 2020 in Review

A.R.T. Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 18,921 shares — an estimated $649K sold.

A.R.T. Advisors first reported a position in ITCI in Q4 2016 and held it in 12 quarters. The position peaked at $2.23M in Q3 2017. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • A.R.T. Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 18,921 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $649K.
  • A.R.T. Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 12 quarters.
  • A.R.T. Advisors's Intra-Cellular Therapies Inc. position peaked at $2.23M in Q3 2017.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.